Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CALM IVF (skape tilknytninger, læring og oppmerksomhet for pasienter med in vitro fertilisering)

30. september 2026 oppdatert av: University of Iowa

Skape tilknytninger, læring og oppmerksomhet for pasienter med in vitro-fertilisering

The investigators have designed a psychoeducational group curriculum specifically for new in vitro fertilization (IVF) patients (both male and female) to improve their treatment knowledge, to allow them to engage more in their care, to offer a support network, to improve satisfaction, and to provide them with tools to help reduce their stress and anxiety while undergoing the IVF process. The investigators plan to have four to eight infertility patients and their partners participate in a group at a time, for which they will attend three 1-1.5 hour interactive sessions that are scheduled throughout their first IVF cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques. They will do several surveys before and after the intervention for comparison, including assessment of quality of life, depression, anxiety, resilience, and a knowledge assessment. The investigators will also track the patients to see if they pursue additional treatment in the instance of a negative pregnancy test compared to patients undergoing the standard treatment. The investigators plan to recruit a control group that receives the standard of care treatment here at the University of Iowa.

Studieoversikt

Detaljert beskrivelse

Patients and their partners (if present and consenting) will be randomized in a 2:1 fashion to two different treatment arms: A) standard of care in vitro fertilization (IVF) at the investigational institution as well as participating in an additional psychoeducational group or B) standard of care IVF at the investigational institution. The intervention group will consist of three additional evening visits for 1-1.5 hours per session. The sessions will include an interactive educational component addressing usual questions and concerns of IVF patients, such as reviewing common IVF myths, and also more information regarding treatment and technologies. Each session will also include teaching of coping strategies (such as awaiting the pregnancy test, how to cope with insensitive remarks from friends and family) as well as relaxation exercises, such as progressive muscle relaxation and deep breathing.

The patients will be consented at their new IVF visit and will take their initial assessments (FertiQoL, GAD-7, PHQ-9, the Connor-Davidson Resilience Scale, and a knowledge assessment) within 24 hours of the new visit. The patients will be assigned into groups based on when they are going through their IVF stimulations, so they will have similar experiences at similar times. Patients will take their final assessments on the third day after egg retrieval, regardless of group assignment.

When partners are present and consent to the study, they will be treated as a dyad with the patient undergoing oocyte retrieval. Some patients go through treatment alone (i.e. single adults desiring pregnancy) and therefore may not have a partner available to participate. Partners level of involvement in a cycle may very, as may their desire to participate in a psychosocial intervention. As patients and their partners make joint decisions throughout their IVF cycle and the cycle itself has a single outcome, we enrolled partners as dyads with patients when partners were present, but did not require a partner to enroll a patient.

Studietype

Intervensjonell

Registrering (Faktiske)

117

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa Hospitals and Clinics

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 99 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • All patients starting their first in vitro fertilization cycle at the University of Iowa Hospitals and Clinics

Exclusion Criteria:

  • Patients who have already undergone in vitro fertilization treatment at any institution
  • Non-English speakers
  • Fertility preservation patients
  • Patients using donor oocytes, embryos, or sperm
  • Patients taking psychotropic medications for depression or anxiety that have had a dosing adjustment within 3 months of study enrollment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervention

Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.

The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.

Annen: Control

Standard of care in vitro fertilization patients at our institution.

Patients will receive the standard of care IVF treatment at the University of Iowa.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in female fertility patient quality of life score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in female GAD-7 score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female PHQ-9 score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female Connor-Davidson Resilience Scale during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in female knowledge assessment during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval
Likelihood of continued IVF treatment in the instance of a negative pregnancy test
Tidsramme: Three months after embryo transfer

Patients who are not pregnant after embryo transfer will be followed for three months to assess likelihood to return for additional treatment after negative embryo transfer outcome.

Three months after embryo transfer
Change in male fertility patient quality of life score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval
Change in male GAD-7 score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male PHQ-9 score during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male Connor-Davidson Resilience Scale during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in male knowledge assessment during IVF treatment cycle
Tidsramme: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Rachel M Whynott, MD, University of Iowa

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. august 2019

Primær fullføring (Faktiske)

9. august 2021

Studiet fullført (Faktiske)

26. oktober 2021

Datoer for studieregistrering

Først innsendt

5. august 2019

Først innsendt som oppfylte QC-kriteriene

5. august 2019

Først lagt ut (Faktiske)

7. august 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere